The dynamics of drug treatment in epilepsy: an observational study in an unselected population based cohort with newly diagnosed epilepsy followed up prospectively over 11-14 years

Journal of Neurology, Neurosurgery, and Psychiatry
S D LhatooS D Shorvon

Abstract

To study prospectively long term dynamics and patterns of treatment in a population based cohort of patients with newly diagnosed epilepsy. 564 patients with definite epilepsy entered the UK National General Practice Study of Epilepsy (NGPSE), between 1984 and 1987, and were prospectively followed up for between 11-14 years. Treatment was started in 433 (77%) patients. Only 15% of single seizure patients had medication prescribed initially, although due to high seizure recurrence, more than 70% ultimately received antiepileptic medication. 209/564 patients (37%) were on drug therapy for epilepsy at the time of last follow up. 168/564 patients (30%) have stayed continuously on medication and another 41/564 patients (7%) restarted drug therapy because of seizure recurrence, having withdrawn medication. 98/209 (47%) of those on treatment are known to be in 5 year terminal remission. Phenytoin (29%) and carbamazepine (27%) were the most commonly preferred first line drugs followed by valproate (15%). Less than half of treated patients with partial seizures received carbamazepine as a first line drug and less than a third with generalised seizures were prescribed valproate as first choice drug. Nine out of 31 (29%) patients with one...Continue Reading

References

Feb 25, 1978·British Medical Journal·S D ShorvonE H Reynolds
Oct 10, 1985·The New England Journal of Medicine·O C Snead, L C Hosey
Nov 1, 1984·Journal of Neurology, Neurosurgery, and Psychiatry·S D Shorvon
Aug 26, 1982·The New England Journal of Medicine·W A HauserS M McRoberts
Nov 1, 1996·Journal of Neurology, Neurosurgery, and Psychiatry·J W Sander, S D Shorvon
Oct 18, 1952·Journal of the American Medical Association·M D YAHRH H MERRITT

❮ Previous
Next ❯

Citations

Apr 5, 2011·Current Neurology and Neuroscience Reports·Heidi Munger Clary, Hyunmi Choi
Dec 4, 2003·Epilepsy Research·P Ryvlin, P Kahane
Nov 26, 2002·Epilepsy Research·Charles L P Deckers
Sep 4, 2010·Annals of Indian Academy of Neurology·P Sarat Chandra, Manjari Tripathi
Oct 18, 2013·British Medical Bulletin·David M G Goodridge, Simon D Shorvon
Nov 3, 2010·Epilepsy Research·Alla GuekhtEugene Gusev
May 26, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A OunM Mägi
Jan 27, 2007·Annals of Neurology·Anna L Luciano, Simon D Shorvon
Sep 16, 2015·Acta Neurologica Scandinavica·M WassenaarUNKNOWN OPPEC study group
Feb 3, 2007·Seizure : the Journal of the British Epilepsy Association·Steve ChungNicole Hank
Nov 16, 2010·Seizure : the Journal of the British Epilepsy Association·Albert P Aldenkamp
Aug 30, 2008·Seizure : the Journal of the British Epilepsy Association·Jan BagshawBrian Chappell
Jan 14, 2009·Seizure : the Journal of the British Epilepsy Association·Helena GauffinBirgitta Söderfeldt
Apr 12, 2014·Epilepsy Research·Linnéa KarlssonTorbjörn Tomson
Sep 15, 2005·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Neil HawkinsMark Sculpher
Sep 15, 2005·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Neil HawkinsDavid Epstein
Jul 27, 2017·Epilepsia·Giorgia GiussaniUNKNOWN EPIRES Group
Mar 10, 2018·Current Neuropharmacology·Irene Aicua-RapunJan Novy
Jun 7, 2017·Acta Neurologica Scandinavica·K BolinA-M Landtblom

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.